A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Life Expectancy for Young People With HIV Is Nearly Normal
Failure to Awaken Dormant Cells Deals Blow to HIV Cure Research
Scientists Devise Method of Snipping HIV From Immune Cells
Media Cooks Up Claim That Soy Sauce Treats, Even Cures HIV
FDA Approves New Single-Tablet HIV Regimen, Triumeq
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

March 7, 2013

For People With HIV, Livalo Lowers LDL Better Than Pravachol

CROI 2013The statin medication Livalo (pitavastatin) is more effective at lowering LDL (“bad”) cholesterol in HIV-positive adults with high cholesterol than another drug in the same class, Pravachol (pravastatin). Kowa Pharmaceuticals America Inc. and Eli Lilly and Company announced the findings of their 12-week, Phase IV, double-blind study at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. In the study, 252 HIV-positive participants, both with and without hepatitis B or C, were randomized one-to-one to receive a daily dose of either 4 mg of Livalo or 40 mg of Pravachol. The primary end point of the study was the percentage drop in LDL cholesterol.  

After 12 weeks of therapy, those taking Livalo saw an average drop in LDL cholesterol of 31 percent, compared with a 21 percent drop in the group taking Pravachol, a difference that was statistically significant, meaning it was too great to have occurred by chance. The percentage of participants experiencing adverse events was similar between the two groups, with 61.1 percent for Livalo and 62.7 percent for Pravachol. The most common adverse events overall included diarrhea, upper respiratory tract infection, sinusitis, headache, nausea, nasal and pharynx inflammation (nasopharyngitis) and an increase in blood creatine phosphokinase. Eleven subjects (4 percent) left the study because of adverse events.

To read the Eli Lilly release, click here.

Search: Livalo, pitavastatin, statin, cholesterol, LDL, Kowa Pharmaceuticals America, Eli Lilly and Company, 20th Conference on Retroviruses and Opportunistic Infections, CROI.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (2 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    acousticmat
    Tucson
    Arizona


    Poz_Qt
    Columbus
    Ohio


    TaintedloveDC
    Washington
    DC


    pozsmith1
    East Bay
    California
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.